1. NF-κB


Receptor activator of NF-κB (RANK) and its ligand receptor activator of NF-κB ligand (RANKL) are encoded, respectively, by the Tumor necrosis factor receptor superfamily member 11A (Tnfrsf11a) and the Tumor necrosis factor ligand superfamily member 11 (Tnfsf11) genes, RANK and RANKL constitute a receptor-ligand pair initiating a signaling pathway of paramount relevance in bone remodeling, lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, and bone metastasis in cancer. RANK mutant mice, as well as RANKL mutant mice, exhibit severe osteopetrosis and defective tooth eruption due to a complete lack in osteoclast. Moreover, RANKL and RANK mutant mice lack lymph nodes and AIRE+ thymic medullary epithelial cells.

RANKL/RANK Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-N10117
    2,3-Bis(3-indolylmethyl)indole 98.42%
    2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
  • HY-N6973
    Boldine Inhibitor 99.57%
    Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK signaling pathway. It can be used in rheumatoid arthritis research[1][2][3].
  • HY-P9958A
    Denosumab (anti-TNFSF11)
    Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells[1].
  • HY-N0499
    Cyanidin Chloride
    Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression[1].
  • HY-N1746
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells[1][2].
  • HY-158311
    Anti-osteoporosis agent-8 Inhibitor
    Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model[1].
  • HY-N6973R
    Boldine (Standard)
    Boldine (Standard) is the analytical standard of Boldine. This product is intended for research and analytical applications. Boldine is an aporphine isoquinoline alkaloid extracted from the root of Litsea cubeba and also possesses these properties, including antioxidant, anti-inflammatory and cytoprotective effects. Boldine suppresses osteoclastogenesis, improves bone destruction by down-regulating the OPG/RANKL/RANK signal pathway and may be a potential therapeutic agent for rheumatoid arthritis[1].
  • HY-162280
    PROTAC BTK Degrader-9 Inhibitor
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model[1].
  • HY-N10062
    Amakusamine Inhibitor
    Amakusamine inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced formation of multinuclear osteoclasts with an IC50 value of 10.5 μM in RAW264.7 cells.
  • HY-P99966
    Narlumosbart Inhibitor
    Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL)[1].